脊髓灰质炎的流行现状及我国疫苗免疫策略的思考

doi:10.3969/j.issn.1006-3110.2022.01.033

摘要
图/表
参考文献
相关文章 (9)

全文: PDF (759 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要现阶段,我国维持无脊髓灰质炎(简称脊灰)状态面临的挑战包括:脊灰野病毒(wild poliovirus,WPV)输入风险的存在、疫苗相关麻痹型脊髓灰质炎(vaccine associated paralytic poliomyelitis,VAPP)病例和脊髓灰质炎疫苗衍生病毒(vaccine-derived poliovirus,VDPV)病例的发生。有必要分析全球消灭脊灰形势的变化,并结合中国维持无脊灰工作进展和需要,就下阶段我国脊灰疫苗免疫策略提出参考建议。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张淑君
	方明礼
	胡向科
	黄铭华
	王志勇
	杨彦华
	颜洁
	赖智维
	高立冬

关键词 ：脊髓灰质炎, 脊髓灰质炎疫苗, 疫苗免疫策略, 疫苗相关麻痹型脊髓灰质炎, 脊髓灰质炎疫苗衍生病毒

Abstract：Currently, the challenges facing China in maintaining polio-free status include the risk of wild poliovirus (WPV) importation and the occurrence of vaccine-associated paralytic poliomyelitis (VAPP) and vaccine-derived poliovirus (VDPV)cases. It is necessary to put forward some suggestions for polio vaccination strategies in China in next stage via analyzing the changes in global polio eradication situation and integrating the progress and demands in maintaining polio-free status in China.

Key words： poliomyelitis poliomyelitis vaccine vaccination strategy vaccine-associated paralytic poliomyelitis vaccine-derived poliovirus

收稿日期: 2021-07-16

:	R186
	R512.4

通讯作者: 高立冬,E-mail:810173358@qq.com。

作者简介: 张淑君(1965-),女,湖南沅江市人,医学硕士,主任医师,主要从事疫苗针对疾病的预防控制工作。张淑君、方明礼同为第一作者。

引用本文:

张淑君, 方明礼, 胡向科, 黄铭华, 王志勇, 杨彦华, 颜洁, 赖智维, 高立冬. 脊髓灰质炎的流行现状及我国疫苗免疫策略的思考[J]. 实用预防医学, 2022, 29(1): 125-129. ZHANG Shu-jun, FANG Ming-li, HU Xiang-ke, HUANG Ming-hua, WANG Zhi-yong, YANG Yan-hua, YAN Jie, LAI Zhi-wei, GAO Li-dong. Current prevalence of poliomyelitis and consideration on polio vaccination strategies in China. , 2022, 29(1): 125-129.

链接本文:

https://www.syyfyx.com/CN/10.3969/j.issn.1006-3110.2022.01.033 或 https://www.syyfyx.com/CN/Y2022/V29/I1/125

[1] World Health Organization. Poliomyelitis fact sheet [EB/OL]. (2019-07-22) [2021-07-20]. https://www.who.int/news-room/fact-sheets/detail/poliomyelitis.
[2] Polio Global Eradication Initiative. Polio eradication and endgame strategic plan 2013-2018[EB/OL]. (2013-02-01) [2021-07-20] https://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf.
[3] World Health Organization. Polio endgame strategy 2019-2023 [EB/OL]. (2019-04-30) [2021-07-20]. https://polioeradication.org/wp-content/uploads/2019/06/english-polio-endgame-strategy.pdf.
[4] Centers for Disease Control and Prevention (CDC). Certification of poliomyelitis eradication-the Americas, 1994[J]. MMWR Morb Mortal Wkly Rep, 1994,43(39):720-722.
[5] Centers for Disease Control and Prevention (CDC). Certification of poliomyelitis eradication-Western Pacific Region, October 2000[J]. MMWR Morb Mortal Wkly Rep, 2001,50(1):1-3.
[6] Centers for Disease Control and Prevention (CDC). Certification of poliomyelitis eradication--European Region, June 2002[J]. MMWR Morb Mortal Wkly Rep, 2002, 51(26):572-574.
[7] World Health Organization. Polio-free certification of the WHO Southeast Asia Region, March 2014[J]. Wkly Epidemiol Rec, 2014, 89(44):500-504.
[8] World Health Organization. Poliomyelitis [EB/OL]. [2021-07-20]. https://www.who.int/health-topics/poliomyelitis#tab=tab_1.
[9] Morales M, Tangermann RH, Wassilak SG. Progress toward polio eradication-worldwide, 2015-2016[J]. MMWR Morb Mortal Wkly Rep, 2016, 65(18):470-473.
[10] World Health Organization. Two out of three wild poliovirus strains eradicated [EB/OL]. (2019-10-24) [2021-07-20]. https://www.who.int/news-room/feature-stories/detail/two-out-of-three-wild-poliovirus-strains-eradicated.
[11] World Health Organization. Global wild poliovirus 2016-2021 [EB/OL]. (2021-06-22) [2021-07-20]. https://polioeradication.org/wp-content/uploads/2021/06/weekly-polio-analyses-WPV-20210622.pdf.
[12] Centers for Disease Control and Prevention (CDC). Resurgence ofwild poliovirus type 1 transmission and consequences of importation-21 countries, 2002-2005[J]. MMWR Morb Mortal Wkly Rep, 2006,55(6):145-150.
[13] Centers for Disease Control and Prevention (CDC). Wild poliovirus type 1 and type 3 importations-15 countries, Africa, 2008-2009[J]. MMWR Morb Mortal Wkly Rep, 2009, 58(14):357-362.
[14] Centers for Disease Control and Prevention (CDC). Outbreaks following wild poliovirus importations-Europe, Africa, and Asia, January 2009-September 2010[J]. MMWR Morb Mortal Wkly Rep, 2010, 59(43):1393-1399.
[15] Yu WZ, Wen N, Zhang Y, et al. Poliomyelitis eradication in China: 1953-2012[J]. J Infect Dis, 2014, 210 (Suppl 1): S268-S274.
[16] Wang HB,Yu WZ,Wang XQ,et al. An outbreak following importation of wild poliovirus in Xinjiang Uyghur Autonomous Region, China, 2011[J]. BMC Infect Dis, 2015, 15:34.
[17] Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden[J]. J Infect Dis, 2014, 210 (Suppl 1): S380-S389.
[18] Wu W, Wang H, Li K, et al. Recipient vaccine-associated paralytic poliomyelitis in China, 2010-2015[J]. Vaccine, 2018, 36(9):1209-1213.
[19] World Health Organization. Polio vaccines: WHO position paper – March, 2016 [J]. Wkly Epidemiol Rec, 2016, 91(12):145-168.
[20] Alleman MM, Jorba J, Greene SA, et al. Update on vaccine-derived poliovirus outbreaks-worldwide, July 2019-February 2020[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(16):489-495.
[21] Wang HB, Luo HM, Li L, et al. Vaccine-derived poliovirus surveillance in China during 2001-2013: the potential challenge for maintaining polio free status[J]. BMC Infect Dis, 2017, 17(1):742.
[22] 李世康, 张帆, 周帅峰, 等. 2017—2018年湖南省急性弛缓性麻痹病例病原学监测分析[J]. 实用预防医学, 2020, 27(4):426-428.
[23] 宁静, 杨宏, 阿迪力, 等. 中国脊髓灰质炎疫苗免疫策略转换后首次在污水中发现Ⅱ型疫苗衍生脊髓灰质炎病毒的应急处置[J]. 中国疫苗和免疫, 2019, 25(4): 373-377,387.
[24] 张倩(编译), 杨宏(审校). 2019年四川省1起Ⅱ型疫苗衍生脊髓灰质炎病毒循环事件的识别和早期应对[J]. 中国疫苗和免疫, 2020, 26(3):357-358.
[25] World Health Organization. WHO/IVB database, as of 14 March 2018. Map production immunization vaccines and biologicals (IVB) [EB/OL]. (2018-03-14) [2021-07-20]. https://www.who.int/entity/immunuzation/monitoring_surveillance/data/schedule_data.xls.
[26] 李娟,李晓梅,张朱佳子, 等. 中国维持无脊髓灰质炎的成绩与挑战[J]. 国际病毒学杂志, 2019, 24(4):5218-5219.
[27] 国家卫生与计划生育委员会疾病预防控制局. 我国响应世卫组织决议实施脊灰疫苗免疫新策略[EB/OL]. (2016-04-29) [2021-07-20]. http://www.nhc.gov.cn/jkj/s3582/201604/8c760a934d5b4d41a81752915c58d304.shtml.
[28] 中华预防医学会. 预防接种知情告知专家共识(上) [J]. 实用预防医学, 2021, 28(4):385-411.
[29] 上海市卫生健康委员会, 上海市中医药管理局. 上海将调整免疫规划脊灰疫苗和含麻疹成分疫苗的免疫程序[EB/OL]. (2020-07-27) [2021-07-20]. http://wsjkw.sh.gov.cn/gzdt1/20200728/d6440867ce9947898e463ba654c8a07f.html.
[30] 中华人民共和国卫生部. 卫生部关于印发《扩大国家免疫规划实施方案》的通知 [EB/OL]. (2008-02-19) [2021-07-20]. http://www.gov.cn/gzdt/2008-02/19/content_893572.htm.
[31] 国家卫生计生委办公厅. 国家卫生计生委办公厅关于印发预防接种工作规范(2016年版)的通知 [EB/OL]. (2016-12-29) [2021-07-20]. http://www.nhc.gov.cn/jkj/s3581/201701/8033406a995d460f894cb4c0331cb400.shtml.
[32] He H, Wang Y, Deng X, et al. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial[J]. Lancet Infect Dis, 2020, 20(9):1071-1079.
[33] Jiang R, Liu X, Sun X, et al. Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population[J]. Vaccine, 2021, 39(9):1463-1471.
[34] Langue J,Matisse N,Pacoret P,et al. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine[J]. Vaccine, 2004, 22(11-12):1406-1414.
[35] Carlsson RM,Claesson BA,Fagerlund E,et al. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy[J]. Ped Inf Dis J, 2002, 21(6):535-541.